statnews.com·May 1, 2026
Axsome has received FDA approval for a treatment targeting agitation in Alzheimer's patients. Additionally, Katherine Szarama has been appointed as the acting head of the FDA's Center for Biologics Evaluation and Research, while tributes are paid to genomics pioneer J. Craig Venter.
Axsome's recent FDA approval for a treatment targeting Alzheimer's-related agitation is a significant milestone, highlighting potential investment opportunities in therapies addressing neuropsychiatric symptoms. For healthtech professionals, monitoring Axsome's progress and similar biotech innovations could provide insights into emerging trends and market dynamics in neurodegenerative disease treatments.